Skip to main content

Table 1 Peer-reviewed data from large phase III trials conducted in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

From: Immunotherapy in head and neck cancer: aiming at EXTREME precision

Study, line (year) N Regimen (treatment arms A, B, C) Response rate (%) Median progression-free survival (months) Median overall survival (months)
ECOG 5397
1st line (2005) [34]
112/ A: P + cetuximabb 26e 4.2 9.2
117 B: P + placebo 10 2.7 8.0
EXTREME
1st line (2008) [18]
442/ A: PF/CF + cetuximabb 36e 5.6e 10.1e
442a B: PF/CF 20 3.3 7.4
SPECTRUM
1st line (2013) [35]
657/ A: PF + panitumumabb 36e 5.8e 11.1
657a B: PF 25 4.6 9.0
IMEX
2nd line (2009) [36]
456/ A: Gefitinib (250 mg)b 2.7 ND 5.6
486a B: Gefitinib (500 mg)b 7.6 ND 6.0
  C: MTX 3.9 ND 6.7
ZALUTE
2nd line (2011) [37]
286/ A: Zb + BSC 6.3 2.3e 6.7
286a B: BSC (optional MTX) 1.1 1.9 5.2
ECOG 1302
2nd line (2013) [38]
177/ A: D + gefitinibb 12.5 3.5 (TTP) 7.3
239a B: D + placebo 6.2 2.1 (TTP) 6.0
LUX-Head&Neck1
2nd line (2015) [39]
483/ A: Afatinibc 10.2 2.6e 6.8
483a B: MTX 5.6 1.7 6.0
CheckMate-141
2nd line (2016) [23]
361/ A: Nivolumabd 13.3e 2.0 7.5e
361a B: MTX or D or cetuximabb 5.8 2.3 5.1
  1. N number of patients analysed for response/efficacy, P cisplatin, C carboplatin, F 5-fluorouracil, MTX methotrexate, Z zalutumumab, BSC best supportive care, D docetaxel, ND no data, TTP time to progression
  2. aintention-to-treat population
  3. bepidermal growth factor receptor inhibitor
  4. cirreversible HER family receptor blocker
  5. dprogrammed cell death protein-1 inhibitor
  6. esignificant differences
\